CORD-19:775b90287b44353bee979abb0970a4666022f86d / 415598-415707 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/775b90287b44353bee979abb0970a4666022f86d","sourcedb":"CORD-19","sourceid":"775b90287b44353bee979abb0970a4666022f86d","text":"A trial of omalizumab for severe, refractory acute urticaria was associated with rapid resolution of disease.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T512","span":{"begin":0,"end":109},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T512","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T512","span":{"begin":0,"end":109},"obj":"Sentence"}],"attributes":[{"subj":"T512","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T2935","span":{"begin":51,"end":60},"obj":"Disease"},{"id":"T24910","span":{"begin":51,"end":60},"obj":"Disease"}],"attributes":[{"id":"A2935","pred":"mondo_id","subj":"T2935","obj":"http://purl.obolibrary.org/obo/MONDO_0005492"},{"id":"A61163","pred":"mondo_id","subj":"T24910","obj":"http://purl.obolibrary.org/obo/MONDO_0005492"},{"subj":"T2935","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T24910","pred":"source","obj":"CORD-19-PD-MONDO"}]},{"project":"CORD-19-PD-HP","denotations":[{"id":"T2039","span":{"begin":51,"end":60},"obj":"Phenotype"}],"attributes":[{"id":"A2039","pred":"hp_id","subj":"T2039","obj":"http://purl.obolibrary.org/obo/HP_0001025"},{"subj":"T2039","pred":"source","obj":"CORD-19-PD-HP"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ec93ce","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93e8ec"},{"id":"CORD-19-PD-MONDO","color":"#ecd593"},{"id":"CORD-19-PD-HP","color":"#bb93ec"}]}]}}